期刊文献+

通心络胶囊联合依那普利治疗2型糖尿病肾病临床观察 被引量:30

Therapeutic effect of Tongxinluo capsule combined with enalapril on type 2 diabetic nephropathy
暂未订购
导出
摘要 目的 观察通心络联合依那普利治疗 2型糖尿病肾病的临床疗效。方法 选用 2型糖尿病肾病 94例随机分为治疗组、对照组 ,治疗组 ( 4 7例 )应用通心络胶囊联合依那普利治疗 ,疗程 4月 ;对照组 ( 4 7例 )仅用依那普利。结果 治疗组降低尿蛋白、改善肾功能作用明显优于对照组 (P <0 .0 5 ) ,且在降血压、改善血糖、调脂等方面的作用亦明显优于对照组 (P <0 .0 5 )。结论 治疗 2型糖尿病肾病患者应用通心络胶囊联合依那普利有较好的改善及保护肾功能 ,减少尿蛋白作用 ,且对 2型糖尿病患者血压、血糖、血脂均有良好的作用 。 Objective To investigate the therapeutic effect of Tongxinluo capsule combined with enalapril on type 2 diabetic nephropathy.Methods 94 patients with type 2 diabetic nephropathy were randomly divided into two groups. 47 patients in treatment group were treated with Tongxinluo capsule combined with enalapril;the other 47 patients in control group were treated with enalapril only,with a treatment course of four months for both groups.Results The effects of reducing proteinuria and improving renal function in treatment group were superior to those in control group (P<0.05); simultaneously in the effects of reducing blood pressure and improving blood glucose and blood lipid (P<0.05).Conclusion Tongxinluo capsule combined with enalapril is effective in treating type 2 diabetic nephropathy, which can protect renal function, reduce proteinuria, decrease blood pressure and improve blood glucose and blood lipid, thus which deserves clinical application.
出处 《疑难病杂志》 CAS 2003年第5期277-279,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 通心络胶囊 依那普利 联合治疗 2型糖尿病肾病 并发症 Type 2 diabetic nephropathy Tongxinluo capsule Enalapril
  • 相关文献

参考文献9

二级参考文献8

  • 1[2]Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J. Clin. Invest. 1985, 76(6):2178.
  • 2[4]Davies PF, Tripathi SC. Mechanical stress mechanism and the cell.An endothelial paradigm. Circ Res, 1993,72(2):239.
  • 3[6]Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin Chim Acta, 2000,297(1-2):135.
  • 4[7]Ceriello A, Quatraro A, Giugliano D. New insights on nonenzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med, 1992,9 (3): 297.
  • 5[8]Maiello M, Boeri D, Podesta F, et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose.Diabetes, 1992,41(8) :1009.
  • 6[9]Shimomura I, Funahashi T, Takahashi M, et al. Enhancedexpression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med, 1996,2(7):800.
  • 7Guh J Y,J Am Soc Nephrol,1996年,7卷,1207页
  • 8Tsao T,Kidney Int,1995年,47卷,1658页

共引文献89

同被引文献217

引证文献30

二级引证文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部